CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers

被引:0
作者
L Kadouri
D F Easton
S Edwards
A Hubert
Z Kote-Jarai
B Glaser
F Durocher
D Abeliovich
T Peretz
R A Eeles
机构
[1] Sharett Institute of Oncology,Department of Endocrinology and Metabolism
[2] Hebrew University-Hadassah Medical Center,undefined
[3] CRC Section of Cancer Genetics,undefined
[4] The Institute of Cancer Research,undefined
[5] CRC Genetic Epidemiology Unit,undefined
[6] Strangeways Research Laboratories,undefined
[7] Hebrew University-Hadassah Medical Center,undefined
[8] Human Genetic Laboratories,undefined
[9] Hebrew University-Hadassah Medical Center,undefined
[10] The Royal Marsden NHS Trust,undefined
来源
British Journal of Cancer | 2001年 / 85卷
关键词
androgen receptor; polymorphisms; breast cancer risk;
D O I
暂无
中图分类号
学科分类号
摘要
Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66 unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test, assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97–1.17) for BC and 1.00 (95%CI 0.83–1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80–1.15) and 0.90 (95%CI 0.60–1.22) respectively for GGC repeats. The corresponding RR estimates for the unselected case–control series were 1.00 (95%CI 0.91–1.10) for the CAG and 1.05 (95%CI 0.90–1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with ≥28 CAG repeats was 1.08 (95%CI 0.45–2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak. © 2001 Cancer Research Campaign http://www.bjcancer.com
引用
收藏
页码:36 / 40
页数:4
相关论文
共 50 条
  • [41] Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants
    Huber, Deborah
    Hatzipanagiotou, Maria
    Schueler-Toprak, Susanne
    Ortmann, Olaf
    Treeck, Oliver
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [42] Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience
    Bufman, Hila
    Faermann, Renata
    Halshtok-Neiman, Osnat
    Shalmon, Anat
    Gotlieb, Michael
    Samoocha, David
    Yagil, Yael
    Feldman, Dana Madorsky
    Friedman, Eitan
    Sklair-Levy, Miri
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (02) : 281 - 285
  • [43] Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience
    Hila Bufman
    Renata Faermann
    Osnat Halshtok-Neiman
    Anat Shalmon
    Michael Gotlieb
    David Samoocha
    Yael Yagil
    Dana Madorsky Feldman
    Eitan Friedman
    Miri Sklair-Levy
    [J]. Breast Cancer Research and Treatment, 2024, 205 : 281 - 285
  • [44] MRI Volumetric Analysis of Breast Fibroglandular Tissue to Assess Risk of the Spared Nipple in BRCA1 and BRCA2 Mutation Carriers
    Heather L. Baltzer
    Olivier Alonzo-Proulx
    James G. Mainprize
    Martin J. Yaffe
    Kelly A. Metcalfe
    Steve A. Narod
    Ellen Warner
    John L. Semple
    [J]. Annals of Surgical Oncology, 2014, 21 : 1583 - 1588
  • [45] Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk
    Luisel J Ricks-Santi
    Lara E Sucheston
    Yang Yang
    Jo L Freudenheim
    Claudine J Isaacs
    Marc D Schwartz
    Ramona G Dumitrescu
    Catalin Marian
    Jing Nie
    Dominica Vito
    Stephen B Edge
    Peter G Shields
    [J]. BMC Cancer, 11
  • [46] BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families
    Cherbal, Farid
    Salhi, Nadjet
    Bakour, Rabah
    Adane, Saida
    Boualga, Kada
    Maillet, Philippe
    [J]. DISEASE MARKERS, 2012, 32 (06) : 343 - 353
  • [47] Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
    Osorio, A.
    Milne, R. L.
    Pita, G.
    Peterlongo, P.
    Heikkinen, T.
    Simard, J.
    Chenevix-Trench, G.
    Spurdle, A. B.
    Beesley, J.
    Chen, X.
    Healey, S.
    Neuhausen, S. L.
    Ding, Y. C.
    Couch, F. J.
    Wang, X.
    Lindor, N.
    Manoukian, S.
    Barile, M.
    Viel, A.
    Tizzoni, L.
    Szabo, C. I.
    Foretova, L.
    Zikan, M.
    Claes, K.
    Greene, M. H.
    Mai, P.
    Rennert, G.
    Lejbkowicz, F.
    Barnett-Griness, O.
    Andrulis, I. L.
    Ozcelik, H.
    Weerasooriya, N.
    Gerdes, A-M
    Thomassen, M.
    Cruger, D. G.
    Caligo, M. A.
    Friedman, E.
    Kaufman, B.
    Laitman, Y.
    Cohen, S.
    Kontorovich, T.
    Gershoni-Baruch, R.
    Dagan, E.
    Jernstrom, H.
    Askmalm, M. S.
    Arver, B.
    Malmer, B.
    Domchek, S. M.
    Nathanson, K. L.
    Brunet, J.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 101 (12) : 2048 - 2054
  • [48] CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world
    Rajender, Singh
    Francis, Amirtharaj
    Pooja, Singh
    Krupakar, Nallala
    Surekha, D.
    Reddy, Gopal
    Rao, D. Raghunatha
    Rao, Lakshmi
    Ramachandra, S.
    Vishnupriya, S.
    Ramalingam, K.
    Satyamoorthy, K.
    Thangaraj, Kumarasamy
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) : 751 - 760
  • [49] CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world
    Singh Rajender
    Amirtharaj Francis
    Singh Pooja
    Nallala Krupakar
    D. Surekha
    Gopal Reddy
    D. Raghunatha Rao
    Lakshmi Rao
    S. Ramachandra
    S. Vishnupriya
    K. Ramalingam
    K. Satyamoorthy
    Kumarasamy Thangaraj
    [J]. Breast Cancer Research and Treatment, 2011, 127 : 751 - 760
  • [50] Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer A systematic review and meta-analysis
    Qin, Zhiqiang
    Li, Xiao
    Han, Peng
    Zheng, Yuxiao
    Liu, Hanyu
    Tang, Jingyuan
    Yang, Chengdi
    Zhang, Jianzhong
    Wang, Kunpeng
    Qi, Xiaokang
    Tang, Min
    Wang, Wei
    Zhang, Wei
    [J]. MEDICINE, 2017, 96 (25)